Structural changes in airway diseases - Characteristics, mechanisms, consequences, and pharmacologic modulation

被引:155
作者
Bergeron, C [1 ]
Boulet, LP [1 ]
机构
[1] Univ Laval, Hop Laval, Ctr Rech, Inst Cardiol & Pneumol, Quebec City, PQ G1V 4C5, Canada
关键词
airway inflammation; airway remodeling; antiasthmatic therapy; asthma; COPD; corticosteroids; cystic fibrosis;
D O I
10.1378/chest.129.4.1068
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
In airway diseases such as asthma and COPD, specific structural changes may be observed very likely secondary to an underlying inflammatory process. Although it is still controversial, airway remodeling may contribute to the development of these diseases and to their clinical expression and outcome. Airway remodeling has been described in asthma in various degrees of severity, and correlations have been found between such features as increase in subepithelial collagen or proteoglyean deposits and airway responsiveness. Although the clinical significance of airway remodeling remains a matter of debate, it has been suggested as a potential target for treatments aimed at reducing asthma severity, improving its control, and possibly preventing its development. To date, drugs used to treat airway diseases have a little influence on airway structural changes. More research should be done to identify key changes, valuable treatments, and proper interventional timing to counteract these changes. The potential of novel therapeutic agents to reverse or prevent airway remodeling is an exciting avenue and warrants further evaluation.
引用
收藏
页码:1068 / 1087
页数:20
相关论文
共 256 条
[31]   Advances in immunology - Asthma [J].
Busse, WW ;
Lemanske, RF .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (05) :350-362
[32]   NEW ANTIALLERGIC PYRANO[3,2-G]QUINOLINE-2,8-DICARBOXYLIC ACIDS WITH POTENTIAL FOR THE TOPICAL TREATMENT OF ASTHMA [J].
CAIRNS, H ;
COX, D ;
GOULD, KJ ;
INGALL, AH ;
SUSCHITZKY, JL .
JOURNAL OF MEDICINAL CHEMISTRY, 1985, 28 (12) :1832-1842
[33]   Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial [J].
Calverley, P ;
Pauwels, R ;
Vestbo, J ;
Jones, P ;
Pride, N ;
Gulsvik, A ;
Anderson, J ;
Maden, C .
LANCET, 2003, 361 (9356) :449-456
[34]   THE STRUCTURE OF LARGE AND SMALL AIRWAYS IN NONFATAL AND FATAL ASTHMA [J].
CARROLL, N ;
ELLIOT, J ;
MORTON, A ;
JAMES, A .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1993, 147 (02) :405-410
[35]   The airway longitudinal elastic fiber network and mucosal folding in patients with asthma [J].
Carroll, NG ;
Perry, S ;
Karkhanis, A ;
Harji, S ;
Butt, J ;
James, AL ;
Green, FHY .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2000, 161 (01) :244-248
[36]   Matrix metalloproteinase-9, but not tissue inhibitor of matrix metalloproteinase-1, increases in the sputum from allergic asthmatic patients after allergen challenge [J].
Cataldo, DD ;
Bettiol, J ;
Noël, A ;
Bartsch, P ;
Foidart, JM ;
Louis, R .
CHEST, 2002, 122 (05) :1553-1559
[37]   Airway remodeling-associated mediators in moderate to severe asthma:: Effect of steroids on TGF-β, IL-11, IL-17, and type I and type III collagen expression [J].
Chakir, J ;
Shannon, J ;
Molet, S ;
Fukakusa, M ;
Elias, J ;
Laviolette, M ;
Boulet, LP ;
Hamid, Q .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2003, 111 (06) :1293-1298
[38]  
Chakir J, 1996, LAB INVEST, V75, P735
[39]   Corticosteroid reversibility in COPD is related to features of asthma [J].
Chanez, P ;
Vignola, AM ;
OShaugnessy, T ;
Enander, I ;
Li, DC ;
Jeffery, PK ;
Bousquet, J .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1997, 155 (05) :1529-1534
[40]   PERSISTENT ASTHMA AFTER REPEATED EXPOSURE TO HIGH-CONCENTRATIONS OF GASES IN PULPMILLS [J].
CHANYEUNG, M ;
LAM, S ;
KENNEDY, SM ;
FREW, AJ .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1994, 149 (06) :1676-1680